Last reviewed · How we verify
Tofacitinib Citrate Tablets — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tofacitinib Citrate Tablets (Tofacitinib Citrate Tablets) — Jiangsu vcare pharmaceutical technology co., LTD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tofacitinib Citrate Tablets TARGET | Tofacitinib Citrate Tablets | Jiangsu vcare pharmaceutical technology co., LTD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tofacitinib Citrate Tablets CI watch — RSS
- Tofacitinib Citrate Tablets CI watch — Atom
- Tofacitinib Citrate Tablets CI watch — JSON
- Tofacitinib Citrate Tablets alone — RSS
Cite this brief
Drug Landscape (2026). Tofacitinib Citrate Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/tofacitinib-citrate-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing